RegeneRx Biopharmaceuticals (RGRX) News Today $0.0014 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartFinancialsSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period EIGRQ Eiger BioPharmaceuticals, Inc.July 19, 2024 | seekingalpha.comRegenerx Biopharmaceuticals Inc RGRXDNovember 5, 2023 | morningstar.comRegenerx Biopharm In (RGRXD)October 31, 2023 | investing.comLIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater ChinaSeptember 21, 2023 | businesswire.comRGRX RegeneRx Biopharmaceuticals, Inc.August 26, 2023 | seekingalpha.comRegeneRx Effects Reverse Stock Split and Terminates SEC Reporting ObligationsAugust 15, 2023 | finance.yahoo.comRegeneRx Receives Stockholder Approval for Reverse Stock SplitAugust 8, 2023 | finance.yahoo.comRegeneRx To Extend Consent Solicitation VoteAugust 1, 2023 | finance.yahoo.comBristol-Myers to Split Off Mead JohnsonJuly 7, 2023 | thestreet.comPlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage InitiationMay 19, 2023 | thestreet.comFirst Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259April 13, 2023 | finance.yahoo.comBiopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030April 7, 2023 | marketwatch.comBiopharmaceutical Third Party Logistics (3PL) Market | 2023-2029April 7, 2023 | marketwatch.com2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029March 1, 2023 | marketwatch.comBiopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028February 25, 2023 | marketwatch.comBiopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027February 24, 2023 | marketwatch.comBiopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)February 12, 2023 | finance.yahoo.comThymosin Beta 4 Research Leads Toward Potential Future Anti-aging TherapyJanuary 31, 2023 | finance.yahoo.com$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are BuyingJanuary 27, 2023 | markets.businessinsider.comBiopharmaceutical Processing Equipment and Consumable Market Size in 2023 Share & Comprehensive Analysis till 2028 [ NEW REPORT ]January 18, 2023 | marketwatch.comBiopharmaceutical CMO & CRO Market Size 2023 with End-user Industries, Segments Covered in the ReportJanuary 17, 2023 | marketwatch.comPublication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic KeratopathyJanuary 3, 2023 | finance.yahoo.comBiopharmaceutical Contract Manufacturing Market, 2035 - Shift from One-time Contracts to Strategic PartnershipsNovember 18, 2022 | finance.yahoo.comRegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye DiseaseOctober 24, 2022 | finance.yahoo.comClover Biopharmaceuticals Ltd (2197)September 30, 2022 | investing.comRegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)September 27, 2022 | finance.yahoo.comRegeneRx Issues 2022 Letter To StockholdersAugust 22, 2022 | finance.yahoo.comRegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic KeratitisJuly 18, 2022 | finance.yahoo.comRegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259June 22, 2022 | finance.yahoo.comTβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the CorneaMay 4, 2022 | finance.yahoo.comRegeneRx Consultant to Receive Prestigious Award for Contributions in Field of HealthFebruary 11, 2022 | finance.yahoo.comRGRX Real-Time QuotesFebruary 7, 2022 | nasdaq.comResearchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol InjuryJanuary 25, 2022 | finance.yahoo.comRGRX After-Hours QuotesJanuary 20, 2022 | nasdaq.comMicrocap RegeneRx surges 17% on regulatory development for ophthalmic candidateJanuary 12, 2022 | seekingalpha.comRegeneRx Publishes Regulatory Update on RGN-259January 12, 2022 | stockhouse.comRegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022December 17, 2021 | finance.yahoo.comRegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye SyndromeNovember 29, 2021 | finance.yahoo.comClinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association MeetingOctober 29, 2021 | finance.yahoo.comResearchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with SepsisOctober 6, 2021 | finance.yahoo.comNew Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's DiseaseOctober 5, 2021 | finance.yahoo.comBeyond Meat's plant-based 'chicken' tenders are coming to grocery storesSeptember 30, 2021 | yahoo.comRegeneRx Licensee Acquired by Korean Biopharmaceutical GroupSeptember 27, 2021 | finance.yahoo.comRegenerx Biopharmaceuticals Inc RGRXJuly 25, 2021 | morningstar.comRegeneRx Issues Letter To StockholdersJuly 22, 2021 | finance.yahoo.com Get RegeneRx Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin RGRX Media Mentions By Week RGRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGRX News Sentiment▼0.000.49▲Average Medical News Sentiment RGRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGRX Articles This Week▼00▲RGRX Articles Average Week Get RegeneRx Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Statera Biopharma News IMV News eFFECTOR Therapeutics News 4Front Ventures News Algernon Pharmaceuticals News Allstar Health Brands News Alvotech News American Premium Mining News Anew Medical News Arno Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RGRX) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RegeneRx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RegeneRx Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
